뉴저지의 골수형성이상증후군 임상 시험
골수형성이상증후군 관련 연구 14개가 뉴저지 내 여러 지역에서 참여자를 모집하고 있습니다.
뉴저지의 도시
공식 연구 텍스트(영어)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
피험자 모집 중1상
12세 ~ 78세 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT03802695Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
- 외 1개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06484062MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooper Hospital University Medical Center, Camden
- Cooperman Barnabas Medical Center, Livingston
- 외 7개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- START New Jersey, East Brunswick
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT05320198Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Cooperman Barnabas Medical Center, Livingston
- Monmouth Medical Center, Long Branch
- Rutgers Cancer Institute of New Jersey, New Brunswick
- 외 1개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06577441The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Hackensack University Medical Center, Hackensack
- Morristown Medical Center, Morristown
- Jersey Shore Medical Center, Neptune City
- 외 3개
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Hackensack Medical Center, Hackensack
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 21. 업데이트됨 · NCT04419649Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Oncology Clinical Research Referral Office, Hackensack
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 10. 업데이트됨 · NCT05308264Mosaic Trial for Stem Cell Transplant Recipients
- Hackensack Meridian Health, Nutley
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 8. 3. 업데이트됨 · NCT06960993Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 7. 7. 업데이트됨 · NCT07216443A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- John Theurer Cancer Center / Hackensack University, Hackensack
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 4. 30. 업데이트됨 · NCT04256317Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 8. 업데이트됨 · NCT06419634A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Atlantic Health, Morristown
- Rutgers Cancer Institute of New Jersey, New Brunswick
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 3. 24. 업데이트됨 · NCT04988555SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Brunswick
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.